Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:10/6/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Oct. 6 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of dirucotide (MBP8298) in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the sixth of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial

----------------

The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of dirucotide (MBP8298) in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of dirucotide (MBP8298) versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... (PRWEB) May 24, 2013 Vestiage, ... lifestyle company focused on science-based research and development, ... anti-aging cosmeceuticals and nutraceuticals, announced today that it ... States for the sale of Reluma Skin Illuminating ... packet and application by sending an email to ...
(Date:5/23/2013)... CASTLE ROCK, Colo. , May 23, 2013 /PRNewswire/ ... vitro diagnostic company focused on obtaining FDA clearance ... APPY1 , today announced the pricing of an underwritten ... and related warrants to purchase 3,500,000 shares of its ... share at a combined public offering price of $1.25 ...
(Date:5/23/2013)... 2013 Patheon Inc ., a ... the global pharmaceutical industry, will host a complimentary webinar ... Testing” on Tuesday, June 4, 2013 at 11 a.m. ... required to comply with regulations for cleaning validation. ... scientific underpinning and little evaluation of risk. Some ...
(Date:5/23/2013)... 23, 2013 PI’s new LPS-24 ... provide 15 mm travel range with closed-loop sensor ... dimensions make these new positioners the ideal choice ... vacuum rated version is also available. , ... datasheets can be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2
... OSLO, Norway, June 17 , ... Shown to Improve Remission Rates and,Reduce Short-Term Mortality Compared ... Pharma ASA (OSE: CLAVIS) today announces positive final results,from ... drug, elacytarabine,(CP-4055), in patients with late-stage acute myeloid leukaemia ...
... ... and Communications Convergence , ... San Diego, CA (PRWEB) June 17, 2009 -- CommNexus and Leap ... unlimited wireless services, today announce their support for EvoNexus, a non-profit incubator dedicated to ...
... by Advanced Cell Technology,s Chief Scientist, Robert Lanza yields answers ... 16 MSNBC.com featured today Dr. Robert Lanza,s book (co-authored ... Consciousness are the Keys to Understanding the True Nature of ... Log." The article by Science Editor Alan Boyle includes ...
Cached Biology Technology:Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 2San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 3San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 4MSNBC Publishes Free Online Abridgment of 'Biocentrism' 2MSNBC Publishes Free Online Abridgment of 'Biocentrism' 3
(Date:5/22/2013)... also conclude that the 20 percent reduction in ... versus chest X-ray (CXR) screening previously reported in ... screening centers in the United States. , Philadelphia, ... patients about the benefits and risks of LDCT ... New England Journal of Medicine of ...
(Date:5/22/2013)... major new effort to educate the public and decision ... clean water that looms ahead in the 21st century. ... current edition of Chemical & Engineering News , ... the world,s largest scientific society. , Bassam Z. Shakhashiri, ... Ph.D., explain that shortages of reliable supplies of fresh ...
(Date:5/22/2013)... health effects from disposal of millions of rechargeable ... recommend stronger government policies to encourage recovery, recycling ... the conclusion of a new paper in the ... , Oladele A. Ogunseitan and colleagues point out ... everything from smart phones to components in new ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... Launches New Multi-Modal Biometric Identification Solution ... Enhanced Performance and Interoperability, SCHAUMBURG, Ill., March ... announced that it has been selected by the ... Biometric Identification,Solution (BIS). Motorola,s latest BIS solution features ...
... a genetic variant that can protect them after heart ... at Washington University School of Medicine in St. Louis ... effect that resembles that of beta blockers, drugs widely ... reason why beta blockers don,t appear to benefit some ...
... Researchers from The University of Arizona and Columbia University ... together and pull with forces far stronger than experts ... including Magdalene Maggie So, a member of the BIO5 ... College of Medicine, studied Type IV pili or ...
Cached Biology News:Motorola Biometric Identification System Selected by West Virginia State Police 2Many African-Americans have a gene that prolongs life after heart failure 2Many African-Americans have a gene that prolongs life after heart failure 3Many African-Americans have a gene that prolongs life after heart failure 4University of Arizona scientist shares in discovery of microbe filaments' power 2
... Analysis Note: Protein determined ... in 3.2 M (NH 4 ... pH 7.0 Preparation Note: Affinity ... sulfate suspension • Additives: MgCl ...
... PP2A, purified MW: 60kDa (A) and ... 20mM MOPS, pH 7.5, 500mM NaCl, ... 0.1mM MnCl2 1mM DTT, and 0.1mg/ml ... vitro dephosphorylation of proteins. Purification: DEAE ...
... Intracellular Localization Kit provides a straight forward ... of your design, in an efficient yet ... Subcellular localization and functional inhibition of target ... of the labeled siRNA into mammalian cells. ...
Selective media for Salmonella...
Biology Products: